118 related articles for article (PubMed ID: 19328320)
1. [Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis: an evolving paradigm].
Dereure O
Ann Dermatol Venereol; 2009 Mar; 136(3):296-7. PubMed ID: 19328320
[No Abstract] [Full Text] [Related]
2. Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis.
Hadfield KD; Newman WG; Bowers NL; Wallace A; Bolger C; Colley A; McCann E; Trump D; Prescott T; Evans DG
J Med Genet; 2008 Jun; 45(6):332-9. PubMed ID: 18285426
[TBL] [Abstract][Full Text] [Related]
3. [Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis: an evolving paradigm].
Dereure O
Ann Dermatol Venereol; 2008 Dec; 135(12):888-9. PubMed ID: 19084709
[No Abstract] [Full Text] [Related]
4. Evidence of a four-hit mechanism involving SMARCB1 and NF2 in schwannomatosis-associated schwannomas.
Sestini R; Bacci C; Provenzano A; Genuardi M; Papi L
Hum Mutat; 2008 Feb; 29(2):227-31. PubMed ID: 18072270
[TBL] [Abstract][Full Text] [Related]
5. SMARCB1 mutations in schwannomatosis and genotype correlations with rhabdoid tumors.
Smith MJ; Wallace AJ; Bowers NL; Eaton H; Evans DG
Cancer Genet; 2014 Sep; 207(9):373-8. PubMed ID: 24933152
[TBL] [Abstract][Full Text] [Related]
6. Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis.
Louvrier C; Pasmant E; Briand-Suleau A; Cohen J; Nitschké P; Nectoux J; Orhant L; Zordan C; Goizet C; Goutagny S; Lallemand D; Vidaud M; Vidaud D; Kalamarides M; Parfait B
Neuro Oncol; 2018 Jun; 20(7):917-929. PubMed ID: 29409008
[TBL] [Abstract][Full Text] [Related]
7. Whole exome sequencing reveals that the majority of schwannomatosis cases remain unexplained after excluding SMARCB1 and LZTR1 germline variants.
Hutter S; Piro RM; Reuss DE; Hovestadt V; Sahm F; Farschtschi S; Kehrer-Sawatzki H; Wolf S; Lichter P; von Deimling A; Schuhmann MU; Pfister SM; Jones DT; Mautner VF
Acta Neuropathol; 2014 Sep; 128(3):449-52. PubMed ID: 25008767
[No Abstract] [Full Text] [Related]
8. Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 2 and Related Disorders.
Evans DGR; Salvador H; Chang VY; Erez A; Voss SD; Druker H; Scott HS; Tabori U
Clin Cancer Res; 2017 Jun; 23(12):e54-e61. PubMed ID: 28620005
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical analysis supports a role for INI1/SMARCB1 in hereditary forms of schwannomas, but not in solitary, sporadic schwannomas.
Patil S; Perry A; Maccollin M; Dong S; Betensky RA; Yeh TH; Gutmann DH; Stemmer-Rachamimov AO
Brain Pathol; 2008 Oct; 18(4):517-9. PubMed ID: 18422762
[TBL] [Abstract][Full Text] [Related]
10. Frequency of SMARCB1 mutations in familial and sporadic schwannomatosis.
Smith MJ; Wallace AJ; Bowers NL; Rustad CF; Woods CG; Leschziner GD; Ferner RE; Evans DG
Neurogenetics; 2012 May; 13(2):141-5. PubMed ID: 22434358
[TBL] [Abstract][Full Text] [Related]
11. Identification of a novel germline SMARCB1 nonsense mutation in a family manifesting both schwannomatosis and unilateral vestibular schwannoma.
Wu J; Kong M; Bi Q
J Neurooncol; 2015 Nov; 125(2):439-41. PubMed ID: 26342709
[No Abstract] [Full Text] [Related]
12. SMARCB1/INI1 maternal germ line mosaicism in schwannomatosis.
Hulsebos TJ; Kenter SB; Jakobs ME; Baas F; Chong B; Delatycki MB
Clin Genet; 2010 Jan; 77(1):86-91. PubMed ID: 19912265
[TBL] [Abstract][Full Text] [Related]
13. SMARCB1 involvement in the development of leiomyoma in a patient with schwannomatosis.
Hulsebos TJ; Kenter S; Siebers-Renelt U; Hans V; Wesseling P; Flucke U
Am J Surg Pathol; 2014 Mar; 38(3):421-5. PubMed ID: 24525513
[TBL] [Abstract][Full Text] [Related]
14. Broadening the spectrum of SMARCB1-associated malignant tumors: a case of uterine leiomyosarcoma in a patient with schwannomatosis.
Paganini I; Sestini R; Cacciatore M; Capone GL; Candita L; Paolello C; Sbaraglia M; Dei Tos AP; Rossi S; Papi L
Hum Pathol; 2015 Aug; 46(8):1226-31. PubMed ID: 26001331
[TBL] [Abstract][Full Text] [Related]
15. SMARCB1/INI1 germline mutations contribute to 10% of sporadic schwannomatosis.
Rousseau G; Noguchi T; Bourdon V; Sobol H; Olschwang S
BMC Neurol; 2011 Jan; 11():9. PubMed ID: 21255467
[TBL] [Abstract][Full Text] [Related]
16. Schwannomatosis: a genetic and epidemiological study.
Evans DG; Bowers NL; Tobi S; Hartley C; Wallace AJ; King AT; Lloyd SKW; Rutherford SA; Hammerbeck-Ward C; Pathmanaban ON; Freeman SR; Ealing J; Kellett M; Laitt R; Thomas O; Halliday D; Ferner R; Taylor A; Duff C; Harkness EF; Smith MJ
J Neurol Neurosurg Psychiatry; 2018 Nov; 89(11):1215-1219. PubMed ID: 29909380
[TBL] [Abstract][Full Text] [Related]
17. Multiple, diffuse schwannomas in a RASopathy phenotype patient with germline KRAS mutation: a causal relationship?
Bertola DR; Pereira AC; Brasil AC; Suzuki L; Leite C; Falzoni R; Tannuri U; Poplawski AB; Janowski KM; Kim CA; Messiaen LM
Clin Genet; 2012 Jun; 81(6):595-7. PubMed ID: 22211815
[No Abstract] [Full Text] [Related]
18. Double somatic SMARCB1 and NF2 mutations in sporadic spinal schwannoma.
Paganini I; Capone GL; Vitte J; Sestini R; Putignano AL; Giovannini M; Papi L
J Neurooncol; 2018 Mar; 137(1):33-38. PubMed ID: 29230670
[TBL] [Abstract][Full Text] [Related]
19. A Rare Case of Familial Schwannomatosis Showing Intrafamilial Variability with Identification of a Shared Novel Germline
Lee JH; Jeong JS; Chae KJ; Han YH; Kim SR; Lee YC
Medicina (Kaunas); 2022 Nov; 58(11):. PubMed ID: 36363549
[TBL] [Abstract][Full Text] [Related]
20. Vestibular schwannomas occur in schwannomatosis and should not be considered an exclusion criterion for clinical diagnosis.
Smith MJ; Kulkarni A; Rustad C; Bowers NL; Wallace AJ; Holder SE; Heiberg A; Ramsden RT; Evans DG
Am J Med Genet A; 2012 Jan; 158A(1):215-9. PubMed ID: 22105938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
